Elucidating Prognosis in Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma: a Novel Anoikis-related Gene Signature Model

Overview

Journal Front Oncol

Specialty Oncology

Date 2024 Jul 11

PMID 38988712

Authors

Mingwei- Wang

Qiaohui- Ying

Ru Ding

Yuncan- Xing

Jue Wang

Yiming- Pan

Bo Pan

Guifen- Xiang

Zhong Liu

Affiliations

Soon will be listed here.

Abstract

Background: Cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC) are among the most prevalent gynecologic malignancies globally. The prognosis is abysmal once cervical cancer progresses to lymphatic metastasis. Anoikis, a specialized form of apoptosis induced by loss of cell adhesion to the extracellular matrix, plays a critical role. The prediction model based on anoikis-related genes (ARGs) expression and clinical data could greatly aid clinical decision-making. However, the relationship between ARGs and CESC remains unclear.

Methods: ARGs curated from the GeneCards and Harmonizome portals were instrumental in delineating CESC subtypes and in developing a prognostic framework for patients afflicted with this condition. We further delved into the intricacies of the immune microenvironment and pathway enrichment across the identified subtypes. Finally, our efforts culminated in the creation of an innovative nomogram that integrates ARGs. The utility of this prognostic tool was underscored by Decision Curve Analysis (DCA), which illuminate its prospective benefits in guiding clinical interventions.

Results: In our study, We discerned a set of 17 survival-pertinent, anoikis-related differentially expressed genes (DEGs) in CESC, from which nine were meticulously selected for the construction of prognostic models. The derived prognostic risk score was subsequently validated as an autonomous prognostic determinant. Through comprehensive functional analyses, we observed distinct immune profiles and drug response patterns among divergent prognostic stratifications. Further, we integrated the risk scores with the clinicopathological characteristics of CESC to develop a robust nomogram. DCA corroborated the utility of our model, demonstrating its potential to enhance patient outcomes through tailored clinical treatment strategies.

Conclusion: The predictive signature, encompassing nine pivotal genes, alongside the meticulously constructed nomogram developed in this research, furnishes clinicians with a sophisticated tool for tailoring treatment strategies to individual patients diagnosed with CESC.

References

Arip M, Tan L, Jayaraj R, Abdullah M, Rajagopal M, Selvaraja M . Exploration of biomarkers for the diagnosis, treatment and prognosis of cervical cancer: a review. Discov Oncol. 2022; 13(1):91. PMC: 9509511. DOI: 10.1007/s12672-022-00551-9. View

Javed S, Bhattacharyya S, Bagga R, Srinivasan R . Insulin growth factor-1 pathway in cervical carcinoma cancer stem cells. Mol Cell Biochem. 2020; 473(1-2):51-62. DOI: 10.1007/s11010-020-03807-6. View

Lopez A, Reyna D, Gitego N, Kopp F, Zhou H, Miranda-Roman M . Co-targeting of BAX and BCL-XL proteins broadly overcomes resistance to apoptosis in cancer. Nat Commun. 2022; 13(1):1199. PMC: 8901805. DOI: 10.1038/s41467-022-28741-7. View

Wang Y, Wang C, Liu N, Hou J, Xiao W, Wang H . HOXC6 promotes cervical cancer progression via regulation of Bcl-2. FASEB J. 2018; 33(3):3901-3911. DOI: 10.1096/fj.201801099RR. View

Siegel R, Miller K, Fuchs H, Jemal A . Cancer Statistics, 2021. CA Cancer J Clin. 2021; 71(1):7-33. DOI: 10.3322/caac.21654. View

Garner T, Lopez A, Reyna D, Spitz A, Gavathiotis E . Progress in targeting the BCL-2 family of proteins. Curr Opin Chem Biol. 2017; 39:133-142. PMC: 5667545. DOI: 10.1016/j.cbpa.2017.06.014. View

Benso A, Di Carlo S, Politano G, Savino A, Hafeezurrehman H . Building gene expression profile classifiers with a simple and efficient rejection option in R. BMC Bioinformatics. 2012; 12 Suppl 13:S3. PMC: 3278843. DOI: 10.1186/1471-2105-12-S13-S3. View

Simon N, Friedman J, Hastie T, Tibshirani R . Regularization Paths for Cox's Proportional Hazards Model via Coordinate Descent. J Stat Softw. 2016; 39(5):1-13. PMC: 4824408. DOI: 10.18637/jss.v039.i05. View

Bilgic S, Domaniku A, Toledo B, Agca S, Weber B, Arabaci D . EDA2R-NIK signalling promotes muscle atrophy linked to cancer cachexia. Nature. 2023; 617(7962):827-834. DOI: 10.1038/s41586-023-06047-y. View

10.

Mereu L, Pecorino B, Ferrara M, Tomaselli V, Scibilia G, Scollo P . Neoadjuvant Chemotherapy plus Radical Surgery in Locally Advanced Cervical Cancer: Retrospective Single-Center Study. Cancers (Basel). 2023; 15(21). PMC: 10648104. DOI: 10.3390/cancers15215207. View

11.

Ge G, Wen Y, Li P, Guo Z, Liu Z . Single-Cell Plasmonic Immunosandwich Assay Reveals the Modulation of Nucleocytoplasmic Localization Fluctuation of ABL1 on Cell Migration. Anal Chem. 2023; 95(48):17502-17512. DOI: 10.1021/acs.analchem.3c02593. View

12.

Ngo-Metzger Q, Adsul P . Screening for Cervical Cancer. Am Fam Physician. 2019; 99(4):253-254. View

13.

Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z . GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017; 45(W1):W98-W102. PMC: 5570223. DOI: 10.1093/nar/gkx247. View

14.

Buskwofie A, David-West G, Clare C . A Review of Cervical Cancer: Incidence and Disparities. J Natl Med Assoc. 2020; 112(2):229-232. DOI: 10.1016/j.jnma.2020.03.002. View

15.

Vickers A, Cronin A, Elkin E, Gonen M . Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers. BMC Med Inform Decis Mak. 2008; 8:53. PMC: 2611975. DOI: 10.1186/1472-6947-8-53. View

16.

Gao Y, Ma X, Lu H, Xu P, Xu C . PLAU is associated with cell migration and invasion and is regulated by transcription factor YY1 in cervical cancer. Oncol Rep. 2022; 49(2). PMC: 9813564. DOI: 10.3892/or.2022.8462. View

17.

Chen D, Guo W, Yu H, Yang J . Construction and validation of prognostic prediction established on N6-methyladenosine related genes in cervical squamous cell carcinoma. Transl Cancer Res. 2022; 11(9):3064-3079. PMC: 9552080. DOI: 10.21037/tcr-22-881. View

18.

Voyle N, Keohane A, Newhouse S, Lunnon K, Johnston C, Soininen H . A Pathway Based Classification Method for Analyzing Gene Expression for Alzheimer's Disease Diagnosis. J Alzheimers Dis. 2015; 49(3):659-69. PMC: 4927941. DOI: 10.3233/JAD-150440. View

19.

Ponten F, Jirstrom K, Uhlen M . The Human Protein Atlas--a tool for pathology. J Pathol. 2008; 216(4):387-93. DOI: 10.1002/path.2440. View

20.

Li J, Cao Q, Tong M . Deciphering anoikis resistance and identifying prognostic biomarkers in clear cell renal cell carcinoma epithelial cells. Sci Rep. 2024; 14(1):12044. PMC: 11130322. DOI: 10.1038/s41598-024-62978-0. View